Award
NIH Reporter #5R01HL170193-03
Targeting Lung Fibrosis Using Epigenetic Therapy
Recipient
University of Kentucky
Award Amount
$673,330.00
Ceiling
$673,330.00
Awarded
August 10, 2026
Identifier
5R01HL170193-03
NIH grant awarded to University of Kentucky for research on epigenetic therapy targeting lung fibrosis using EZH2 inhibition, with a total funding of $673,330 for the fiscal year 2026.
Description
This research aims to validate the use of EZH2 inhibition as a treatment for pulmonary fibrosis, expanding knowledge in lung epigenetics and stem cell biology. The study involves both in vitro and in vivo models, including human and mouse organotypic cultures, lung injury models, and patient tissue analysis.